QQQ   261.11 (+0.28%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
QQQ   261.11 (+0.28%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
QQQ   261.11 (+0.28%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
QQQ   261.11 (+0.28%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

$39.96
+1.31 (+3.39 %)
(As of 07/15/2020 01:28 PM ET)
Add
Compare
Today's Range
$39.09
Now: $39.96
$40.48
50-Day Range
$34.03
MA: $37.73
$43.44
52-Week Range
$20.03
Now: $39.96
$54.97
Volume192,244 shs
Average Volume469,602 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Read More
Regenxbio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.23 million
Book Value$12.23 per share

Profitability

Net Income$-94,730,000.00
Net Margins-197.23%

Miscellaneous

Employees192
Market Cap$1.49 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

Regenxbio (NASDAQ:RGNX) Frequently Asked Questions

How has Regenxbio's stock been impacted by COVID-19 (Coronavirus)?

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX shares have increased by 21.5% and is now trading at $39.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Regenxbio?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

When is Regenxbio's next earnings date?

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

How were Regenxbio's earnings last quarter?

Regenxbio Inc (NASDAQ:RGNX) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.21. The biotechnology company had revenue of $17.60 million for the quarter, compared to the consensus estimate of $17.99 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. The firm's revenue was up 1855.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.89) earnings per share. View Regenxbio's earnings history.

What price target have analysts set for RGNX?

6 brokerages have issued 12-month price targets for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's share price to reach $68.33 in the next twelve months. This suggests a possible upside of 71.0% from the stock's current price. View analysts' price targets for Regenxbio.

Has Regenxbio been receiving favorable news coverage?

Press coverage about RGNX stock has trended negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regenxbio earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Regenxbio.

Who are some of Regenxbio's key competitors?

What other stocks do shareholders of Regenxbio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Who are Regenxbio's key executives?

Regenxbio's management team includes the following people:
  • Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
  • Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
  • Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)
  • Dr. Olivier Danos, Chief Scientific Officer (Age 61)
  • Dr. Stephen Yoo, Consultant (Age 41)

What is Regenxbio's stock symbol?

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Who are Regenxbio's major shareholders?

Regenxbio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Exane Derivatives (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio.

Which major investors are buying Regenxbio stock?

RGNX stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives. View insider buying and selling activity for Regenxbio.

How do I buy shares of Regenxbio?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regenxbio's stock price today?

One share of RGNX stock can currently be purchased for approximately $39.96.

How big of a company is Regenxbio?

Regenxbio has a market capitalization of $1.49 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

What is Regenxbio's official website?

The official website for Regenxbio is www.regenxbio.com.

How can I contact Regenxbio?

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.